YD Bio (YDESW) Share-based Compensation (2026)
YD Bio's (YDESW) quarterly Share-based Compensation came in at $30000.0 in Q2 2026.
Powered by 
Analysis
YD Bio (YDESW) Share-based Compensation (2026) Analysis & Trends
YD Bio (YDESW) has reported Share-based Compensation for 1 consecutive years, with $30000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Share-based Compensation changed N/A year-over-year to $30000.0 in Q2 2026; TTM through Jun 2026 was $30000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $20471.0, up 74.5% from the prior year.
- Share-based Compensation was $30000.0 for Q2 2026 at YD Bio.
- Over five years, Share-based Compensation peaked at $30000.0 in Q2 2026 and troughed at $30000.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.05 Bn | 198.06 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 181.76 Bn | 178.58 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.46 Bn | 124.61 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 82.66 Bn | 74.67 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 61.56 Bn | 56.37 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.56 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.46 Bn | 30.17 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 30.15 Bn | 30.15 Bn | 1.16 Mn | 83.34 Mn |
| 10 | YD Bio | 29.02 Mn | 26.36 Mn | - | 30,000.00 |